Phaseline

Targets › CRLF2

CRLF2 (Cytokine receptor-like factor 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2030.

Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. (UniProt, Q9HC73)

Open in Phaseline: the race on CRLF2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)TSLPR-CART
Anti-CRLF2 chimeric antigen receptor T cell therapy
CRLF2Phase 1B-AllJun 2030

Conditions

B-All (1)

Modalities

mixed (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.